From: Going beyond the mean: economic benefits of myocardial infarction secondary prevention
Prophylactic medication | Traj. Group | Full population N compliant (%) | Multivariable RRR [95%CI] | p-value | Not pre-exposed N compliant (%) | Multivariable RRR [95%CI] | p-value |
---|---|---|---|---|---|---|---|
4-class combination (main analysis) | 1 | 478/1302 (36.7) | Ref. | 0.0191 | 192/429 (44.8) | Ref. | 0.5253 |
2 | 71/245 (29.0) | 0.89 [0.65; 1.22] | 25/62 (40.3) | 0.84 [0.47; 1.50] | |||
3 | 22/87 (25.3) | 0.71 [0.42; 1.21] | 8/14 (57.1) | 2.29 [0.67; 7.88] | |||
4 | 3/31 (9.7) | 0.20 [0.06; 0.71] | 5/12 (41.7) | 0.81 [0.24; 2.77] | |||
3- & 4-class combinations (sensitivity analysis) | 1 | 353/1302 (27.1) | Ref. | 0.5457 | 134/429 (31.2) | Ref. | 0.4777 |
2 | 65/245 (26.5) | 1.07 [0.77; 1.48] | 20/62 (32.3) | 1.19 [0.65; 2.16] | |||
3 | 28/87 (32.2) | 1.44 [0.88; 2.34] | 2/14 (14.3) | 0.38 [0.07; 1.95] | |||
4 | 7/31 (22.6) | 0.96 [0.40; 2.34] | 4/12 (33.3) | 1.24 [0.34; 4.46] |